Please login to the form below

Not currently logged in
Email:
Password:

IL-17 inhibitor

This page shows the latest IL-17 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Amgen’s R&D chief Sean Harper retires to seek biotech post

Amgen’s R&D chief Sean Harper retires to seek biotech post

from biosimilars and newer drugs such as Novartis’fast-growing IL-17 inhibitor Cosentyx (secukinumab).

Latest news

  • GSK sells eczema and psoriasis drug to Dermavant for £250m GSK sells eczema and psoriasis drug to Dermavant for £250m

    The cut included IL-6 inhibitor sirukumab for rheumatoid arthritis, which left tapinarof as the lead candidate in its immuno-inflammation programme. ... In the case of psoriasis, that includes not only new therapies such as Novartis’IL-17 inhibitor

  • UK, Germany back routine use of J&J’s Tremfya UK, Germany back routine use of J&J’s Tremfya

    psoriasis therapies such as Novartis’fast-growing IL-17 inhibitor Cosentyx (secukinumab), which EvaluatePharma expects to become a $4.6bn product by 2022. ... Add in additional IL-17 inhibitors for Eli Lilly and Valeant and the market for biologics for

  • Lilly claims another EU okay for Taltz Lilly claims another EU okay for Taltz

    Lilly claims another EU okay for Taltz. The IL-17 inhibitor can be used alone or in combination with methotrexate for PsA patients. ... Eli Lilly’s new immunotherapy Taltz has picked up a second indication in Europe, with the EMA approving the IL-17

  • Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown

    The two trials - SURPASS and EXCEED - will compare interleukin-17 antagonist Cosentyx (secukinumab) against TNF blocker adalimumab in ankylosing spondylitis and psoriatic arthritis, respectively. ... Cosentyx was the first IL-17 inhibitor to reach the

  • Janssen’s Tremfya cleared for European use Janssen’s Tremfya cleared for European use

    therapy. The drug is a follow-up for its IL-23/IL-12 inhibitor Stelara, which is facing competition from newer psoriasis drugs showing greater efficacies in clinical trials. ... However, only 49.7% and 46.8% of patients taking Humira achieved a PASI 90,

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics